Cargando…
Assessing developability early in the discovery process for novel biologics
Beyond potency, a good developability profile is a key attribute of a biological drug. Selecting and screening for such attributes early in the drug development process can save resources and avoid costly late-stage failures. Here, we review some of the most important developability properties that...
Autores principales: | Fernández-Quintero, Monica L., Ljungars, Anne, Waibl, Franz, Greiff, Victor, Andersen, Jan Terje, Gjølberg, Torleif T., Jenkins, Timothy P., Voldborg, Bjørn Gunnar, Grav, Lise Marie, Kumar, Sandeep, Georges, Guy, Kettenberger, Hubert, Liedl, Klaus R., Tessier, Peter M., McCafferty, John, Laustsen, Andreas H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980699/ https://www.ncbi.nlm.nih.gov/pubmed/36823021 http://dx.doi.org/10.1080/19420862.2023.2171248 |
Ejemplares similares
-
Comparison of hydrophobicity scales for predicting biophysical properties of antibodies
por: Waibl, Franz, et al.
Publicado: (2022) -
Conformational Ensembles of Antibodies Determine Their Hydrophobicity
por: Waibl, Franz, et al.
Publicado: (2021) -
PEP-Patch: Electrostatics in Protein–Protein
Recognition, Specificity, and Antibody Developability
por: Hoerschinger, Valentin J., et al.
Publicado: (2023) -
Discovery and optimization of a broadly-neutralizing human monoclonal antibody against long-chain α-neurotoxins from snakes
por: Ledsgaard, Line, et al.
Publicado: (2023) -
Phage display assisted discovery of a pH‐dependent anti‐α‐cobratoxin antibody from a natural variable domain library
por: Tulika, Tulika, et al.
Publicado: (2023)